Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8079MR)

This product GTTS-WQ8079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8079MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6538MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ15751MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ11849MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ6549MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA D2E7
GTTS-WQ2553MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
GTTS-WQ12455MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ6650MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ1167MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW